Loading...
Loading...
NXTC| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.1M |
| Gross Profit | -1.1M |
| Operating Expense | 19.2M |
| Operating I/L | -19.2M |
| Other Income/Expense | 1.3M |
| Interest Income | 0.0M |
| Pretax | -17.9M |
| Income Tax Expense | 0.8M |
| Net Income/Loss | -17.9M |
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunomedicines to treat cancer and immune-related diseases by restoring normal immune function. Its lead product candidate, NC318, is in Phase II clinical trials for advanced or metastatic solid tumors. The company is also developing NC410, a Phase I immunomedicine targeting immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, targeting human B7 homolog 4 protein; and NC525, a novel LAIR-1 antibody in preclinical trials for acute myeloid leukemia. NextCure also has a license agreement with Yale University for its research programs.
